JMP Securities Reiterates “Market Outperform” Rating for CureVac (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC)‘s stock had its “market outperform” rating reiterated by analysts at JMP Securities in a research report issued on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock. JMP Securities’ price objective would suggest a potential upside of 338.36% from the company’s current price.

CureVac Price Performance

NASDAQ:CVAC opened at $3.65 on Friday. CureVac has a 12 month low of $2.21 and a 12 month high of $5.28. The stock has a 50 day moving average of $3.62 and a two-hundred day moving average of $3.22. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The firm has a market cap of $817.16 million, a P/E ratio of 6.64 and a beta of 2.51.

Institutional Investors Weigh In On CureVac

A number of large investors have recently made changes to their positions in the stock. Northern Trust Corp grew its position in shares of CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company’s stock valued at $205,000 after purchasing an additional 29,759 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of CureVac in the fourth quarter valued at approximately $55,000. XTX Topco Ltd grew its position in shares of CureVac by 90.2% in the fourth quarter. XTX Topco Ltd now owns 24,365 shares of the company’s stock valued at $83,000 after purchasing an additional 11,553 shares in the last quarter. Barclays PLC grew its position in CureVac by 51.8% in the fourth quarter. Barclays PLC now owns 34,836 shares of the company’s stock worth $118,000 after acquiring an additional 11,890 shares during the period. Finally, Quadrant Capital Group LLC grew its position in CureVac by 61.8% in the fourth quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company’s stock worth $171,000 after acquiring an additional 19,098 shares during the period. 17.26% of the stock is currently owned by hedge funds and other institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.